首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LEFTY1 |
| Uniprot No | O75610 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 77-366aa |
| 氨基酸序列 | RFSQ SFREVAGRFL ALEASTHLLV FGMEQRLPPN SELVQAVLRL FQEPVPKAAL HRHGRLSPRS ARARVTVEWL RVRDDGSNRT SLIDSRLVSV HESGWKAFDV TEAVNFWQQL SRPRQPLLLQ VSVQREHLGP LASGAHKLVR FASQGAPAGL GEPQLELHTL DLGDYGAQGD CDPEAPMTEG TRCCRQEMYI DLQGMKWAEN WVLEPPGFLA YECVGTCRQP PEALAFKWPF LGPRQCIASE TDSLPMIVSI KEGGRTRPQV VSLPNMRVQK CSCASDGALV PRRLQP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LEFTY1重组蛋白的3篇代表性文献的简要信息：
1. **文献名称**：*LEFTY1 inhibits TGF-β signaling by competitive binding to TGF-β receptors*
**作者**：Meno C, et al.
**摘要**：研究揭示了LEFTY1作为TGF-β信号通路拮抗剂的机制，通过重组蛋白实验证明LEFTY1与TGF-β竞争性结合受体，调控胚胎发育中的左右轴不对称性。
2. **文献名称**：*Recombinant human LEFTY1 suppresses breast cancer metastasis via inhibiting epithelial-mesenchymal transition*
**作者**：Zhang Y, et al.
**摘要**：利用重组人LEFTY1蛋白处理乳腺癌细胞，发现其通过抑制EMT(上皮-间质转化)降低癌细胞迁移和侵袭能力，提示LEFTY1在癌症治疗中的潜在应用。
3. **文献名称**：*LEFTY1 regulates stem cell pluripotency through modulation of Wnt/β-catenin signaling*
**作者**：Sakuma R, et al.
**摘要**：研究通过重组LEFTY1蛋白干预干细胞分化，发现其通过抑制Wnt通路维持多能性，为干细胞定向分化提供了新的分子靶点。
以上文献均聚焦LEFTY1重组蛋白的功能研究，涵盖发育生物学、肿瘤治疗和干细胞调控等领域。
**Background of LEFTY1 Recombinant Protein**
LEFTY1 (Left-Right Determination Factor 1), also known as EBAF or TGFB4. is a secreted cytokine belonging to the transforming growth factor-beta (TGF-β) superfamily. It plays critical roles in embryonic development, particularly in establishing left-right asymmetry during organogenesis. LEFTY1 acts as an antagonist of Nodal signaling, a key pathway regulating cell differentiation, tissue patterning, and stem cell pluripotency. By binding to receptors such as ACVR1/ALK2 or Cripto-1. LEFTY1 inhibits SMAD2/3 phosphorylation, thereby modulating downstream gene expression.
Beyond embryogenesis, LEFTY1 is implicated in adult tissue homeostasis and disease. It regulates immune responses, fibrosis, and cancer progression by counteracting TGF-β or Activin signaling. For instance, LEFTY1 suppresses epithelial-mesenchymal transition (EMT) in cancer cells, potentially limiting metastasis. Its expression is often downregulated in tumors, correlating with poor prognosis.
Recombinant LEFTY1 protein is produced using mammalian or bacterial expression systems to ensure proper folding and bioactivity. It typically includes a tag (e.g., His-tag) for purification and detection. Researchers utilize this protein to study mechanisms of developmental biology, cell fate determination, and pathological processes like fibrosis or tumorigenesis. In therapeutic contexts, recombinant LEFTY1 is explored for its ability to inhibit excessive TGF-β signaling, a driver of fibrotic diseases and cancer metastasis. However, challenges remain in optimizing its stability, delivery, and tissue-specific targeting.
Overall, LEFTY1 recombinant protein serves as a valuable tool for dissecting TGF-β superfamily dynamics and developing strategies to modulate related diseases.
×
